Skip to main content.

Sahil M. Pandya, M.D.

Sahil Pandya portrait
Assistant Professor, Pulmonary, Critical Care and Sleep Medicine

Assistant Professor, Kansas City Veteran's Affairs Medical Center, Pulmonary, Critical Care and Sleep Medicine

Associate Program Director, Pulmonary and Critical Care Fellowship, Pulmonary, Critical Care and Sleep Medicine

spandya2@kumc.edu

Professional Background

Dr. Pandya is a Pulmonary and Critical Care Specialist at the University of Kansas Medical center and shares a joint appointment at the Veteran's Affairs Medical Center.

He completed his medical school training at Northeast Ohio Medical University - as one of 30 students in the country to be selected in the accelerated BS/MD program. He went on to complete his Internal Medicine residency training at Rush University Medical Center in Chicago, IL. He ultimately completed his fellowship in Pulmonary/Critical Care at the University of Kansas Medical Center.

His clinical focuses of interest include Interstitial Lung Disease and Rare Lung Diseases within the subspecialty of Pulmonology. He possesses clinical expertise in treating conditions that include: Idiopathic Pulmonary Fibrosis (IPF), Sarcoidosis, Hypersensitivity Pneumonitis, Vasculitis, Connective Tissue Related Interstitial Lung Disease (including Scleroderma and Sjogren's Syndrome, Dermatomyositis and Polymyositis) and Rare Lung Disease (LAM, Langerhan's Histiocytosis and other Cystic Lung Diseases).

He has a special interest in Pulmonary based procedures both in the Intensive Care Unit and in the Outpatient Setting. These procedures include: Bronchoscopy with Lavage, Endobronchial Ultrasound (EBUS), Thoracentesis and Chest Tube Insertion.

Within academic medicine he is a clinician educator and serves as core faculty in the Internal Medicine Residency and is the Associated Program Director of the Pulmonary and Critical Care Fellowship. He has received several distinguished teaching awards at the medical student, resident and fellow levels.

Education and Training
  • BS, Integrated Life Sciences, Kent State University, Kent, OH
  • MD, Doctor of Medicine, Northeast Ohio Medical University, Rootstown, OH
  • Residency, Internal Medicine, Rush University Medical Center, Chicago, IL
  • Clinical Fellowship, Pulmonary and Critical Care, University of Kansas Medical Center, Kansas City, KS
Licensure, Accreditations & Certifications
  • Critical Care Medicine , American Board of Internal Medicine
  • Doctor of Medicine, Kansas State Board of Healing Arts
  • Doctor of Medicine, Missouri Board of Registration for the Healing Arts
  • Internal Medicine, American Board of Internal Medicine
  • Pulmonary Disease, American Board of Internal Medicine
Professional Affiliations
  • Pulmonary Fibrosis Foundation, Member, 2019 - Present
  • American Thoracic Society, Member, 2017 - Present
  • CHEST, Member, 2017 - Present
  • Society of Critical Care Medicine, Member, 2017 - Present

Research

Overview

Dr. Pandya has a wide range of research interests within Pulmonary and Critical Care.

From a clinician educator perspective - he has a special interest in procedural coaching and simulation based education. He has worked to develop curricula for pulmonary procedures including bronchoscopy, thoracentesis and procedural tracks for internal medicine residents.

He is involved with several clinical trials in the field of Interstitial Lung Disease and Sarcoidosis that treats patients with progressive lung disease and rapidly declining lung function.

Dr. Pandya also strongly values inter-professional research initiatives, and has devoted a large amount of research time to explore the disease burden of Histoplasmosis and is systemic and pulmonary manifestations over time.

He has future research interests that are ongoing on the Pulmonary manifestations of COVID 19 and its morbidity related to patient care over time.

Current Research and Grants
  • A Multicenter, Randomized, Doubleblind, Placebocontrolled, Phase 2 Study of the Efficacy and the Safety and Tolerability of BMS‐ 986278 in Participants with Pulmonary Fibrosis, Bristol Meyers Squibb, Sub-Investigator
  • A Randomized, Double Blind, Placebo Controlled Phase 2 Study with Open Label Extension to Assess Efficacy and Safety of Namilumab in Subjects with Chronic Pulmonary Sarcoidosis, Kinevant, PI
  • A subject and investigator blinded, randomized, placebocontrolled, repeat-dose, multicenter study to investigate efficacy, safety, and tolerability of CMK389 in patients with Chronic Pulmonary Sarcoidosis , Novartis, PI
  • Evaluation of Efficacy and Safety of Pamrevulumab in Patients with Idiopathic Pulmonary Fibrosis, Fibrogen, Sub-Investigator
  • Phase 2b Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects with Idiopathic Pulmonary Fibrosis, Horizons Therapeutics, PI
  • Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis (TETON), United Therapeutics , PI
Publications
  • Greg, Jennifer, Pandya, Sahil, Model, Michael. 2010. Measurement of Cell Volume and Membrane Integrity in Adherent Cells. Journal of General Physiology, 136, 503-509
  • Gregg, Jennifer, Pandya, Sahil, Model, Michael. 2010. Measurement of the Thickness and Volume of adherent cells using transmission-through-dye microscopy. European Journal of Physiology , 460 (6), 1097
  • Pelts, Mariana, Pandya, Sahil, Model, Michael. 2011. Thickness profiling of formaldehyde fixed cells by transmission through dye microscopy. BioTechniques, 50, 386-389